Pharmala Biotech Holdings Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDMA.CN research report →
Companypharmala.ca
Pharmala Biotech Holdings Inc. , doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds.
- CEO
- Nicholas Kadysh
- IPO
- 2022
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $17.97M
- P/E
- -11.00
- P/S
- 20.20
- P/B
- 8.33
- EV/EBITDA
- -11.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -58.85%
- Op Margin
- -179.73%
- Net Margin
- -183.55%
- ROE
- -67.05%
- ROIC
- -74.15%
Growth & Income
- Revenue
- $605.50K · -41.51%
- Net Income
- $-2,175,244 · -164.12%
- EPS
- $-0.02 · -134.41%
- Op Income
- $-2,153,225
- FCF YoY
- -91.06%
Performance & Tape
- 52W High
- $0.20
- 52W Low
- $0.09
- 50D MA
- $0.13
- 200D MA
- $0.12
- Beta
- 0.70
- Avg Volume
- 192.79K
Get TickerSpark's AI analysis on MDMA.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MDMA.CN Coverage
We haven't published any research on MDMA.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MDMA.CN Report →